Correspondence 0001193125-23-279802 from Tarsus Pharmaceuticals, Inc. (TARS) (CIK 0001819790) (TARS)
Tarsus Pharmaceuticals, Inc. (TARS) (CIK 0001819790)
Date: Nov. 17, 2023 · CIK: 0001819790 · Accession: 0001193125-23-279802
AI Filing Summary & Sentiment
File numbers found in text: 333-275439
Letter
Tarsus Pharmaceuticals, Inc.
15440 Laguna Canyon Road, Suite 160
Irvine, California 92618
November 17, 2023
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance
100 F Street N.E.
Washington, D.C. 20549
Re: Tarsus Pharmaceuticals, Inc.
Registration Statement on Form S-3, filed November 9, 2023
(File No. 333-275439)
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, Tarsus Pharmaceuticals, Inc. (the “Registrant”) hereby requests that the Securities and Exchange Commission accelerate the effectiveness of the above-referenced Registration Statement, to 4:00 p.m., Eastern Time, on Tuesday, November 21, 2023, or as soon thereafter as practicable.
The Registrant hereby authorizes Ryan Gunderson of Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP, counsel to the Registrant, to orally modify or withdraw this request for acceleration.
Thank you for your assistance. If you should have any questions, please contact Ryan Gunderson of Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP, counsel to the Registrant, at (858) 436-8046.
Thank you for your attention on this matter.
Very truly yours,
Tarsus Pharmaceuticals, Inc.
Show Raw Text
CORRESP 1 filename1.htm CORRESP Tarsus Pharmaceuticals, Inc. 15440 Laguna Canyon Road, Suite 160 Irvine, California 92618 November 17, 2023 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street N.E. Washington, D.C. 20549 Re: Tarsus Pharmaceuticals, Inc. Registration Statement on Form S-3, filed November 9, 2023 (File No. 333-275439) Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, Tarsus Pharmaceuticals, Inc. (the “Registrant”) hereby requests that the Securities and Exchange Commission accelerate the effectiveness of the above-referenced Registration Statement, to 4:00 p.m., Eastern Time, on Tuesday, November 21, 2023, or as soon thereafter as practicable. The Registrant hereby authorizes Ryan Gunderson of Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP, counsel to the Registrant, to orally modify or withdraw this request for acceleration. Thank you for your assistance. If you should have any questions, please contact Ryan Gunderson of Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP, counsel to the Registrant, at (858) 436-8046. Thank you for your attention on this matter. Very truly yours, Tarsus Pharmaceuticals, Inc. By: /s/ Jeffrey Farrow Jeffrey Farrow Chief Financial Officer and Chief Strategy Officer cc: Ryan Gunderson, Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP